Lupin, Zentiva ink pact for biosimilar
Lupin and pan-European pharmaceutical company Zentiva Group have entered into a license and supply agreement for commercialisation of Lupin’s biosimilar Certolizumab Pegol across multiple markets globally. They will invest in the development of the biosimilar. Lupin will receive an initial payment of $10 million upon execution of the agreement and total development and regulatory […]
Continue Reading
